Sales of Celgene’s marquee cancer drug surge as Trump’s price-crackdown looms | Washington Examiner

Celgene itself filed a lawsuit earlier this year to block Dr. Reddy’s Laboratories from selling a generic version of Revlimid, but doesn’t expect to make it to court in the near future.

“We don’t see a trial at all this year, and it’s very, very difficult to know if something would be scheduled for 2019,” Chief Executive Officer Mark Alles told investors.

The pharmaceutical industry is bracing for President Trump to unveil a drug-pricing plan, details of which are largely unknown but have been hinted at by FDA Commissioner Scott Gottlieb. Changes to the risk program might be among them, based on Gottlieb’s urging of brand-name manufacturers to “end the shenanigans” with it.

Lawmakers, who have tried for years to push forward legislation that would address concerns with the REMS program, have encountered resistance from both the pharmaceutical lobby and companies like Celgene, according to drug lobbyists and congressional aides.

Read complete article here:

Sales of Celgene’s marquee cancer drug surge as Trump’s price-crackdown looms.